• Asia Pacific focused Biosimilars event in Singapore
  •  Latest Biosimilar Case Studies
  •   Country focused updates

Over the past year, the number of biosimilar development projects which have been publically disclosed has increased by approximately 40 percent with demand in Asia gaining momentum.

Asia Pacific countries are actively working to formulate biosimilars guidelines and promoting itself as an attractive destination for biosimilar companies to set up manufacturing and R&D facilities. IBC’s Biosimilars Asia Pacific conference evaluates the region’s market readiness and future uptake of biosimilars, development of regulatory frameworks and best practice commercialization strategies.

2015 Highlights

  • Biosimilar investment opportunities in Asia Pacific
  • Strategic market access in regulated and less regulated markets
  • Latest regulatory developments and approvals in Europe, United States, Southeast Asia and China
  • Business models and cost effective approaches to advance biosimilar development
  • Insights on key success factors in a win-win partnership

View all speakers »

 

2015 Featured Speakers

Ming Wang
Vice President, Diabetes Disease Area Leader, Janssen Pharmaceuticals, USA

Haizhou (Joe) Zhang
Executive Deputy Head, Center of Medical and Translational Sciences, Shanghai CP Guojian Pharmaceutical, China

George Wang
Founder and Chief Executive Officer, Mab-Venture Co. Ltd., China
Mudgal Kothekar
DGM Clinical Development & Head Pharmacovigilance, Biocon Research Limited, India

 

Produced by   

 

 

 
Past Media Partners